Idecabtagene Vicleucel治疗复发/难治性多发性骨髓瘤:来自骨髓瘤CAR-T联盟的真实世界经验
本研究回顾性收集了11家美国机构中接受标准治疗ide-cel的复发/难治性多发性骨髓瘤患者数据,196例白细胞采集患者中159例接受输注。最佳总缓解率和≥完全缓解率分别为84%和42%,中位无进展生存期8.5个月,中位总生存期12.5个月,安全性与KarMMa试验相当。
要点
- 标准治疗ide-cel的最佳总缓解率为84%,≥完全缓解率为42%。
- 中位随访6.1个月时,中位无进展生存期为8.5个月,中位总生存期为12.5个月。
- 既往BCMA靶向治疗、高危细胞遗传学、ECOG体能状态评分≥2和较年轻年龄与更差的无进展生存期相关。
核心结论
- 在标准治疗背景下,ide-cel对复发/难治性多发性骨髓瘤患者的安全性和疗效与II期关键KarMMa试验相当,尽管大多数患者(75%)不符合试验入组标准。
研究设计与样本
- 回顾性收集自2022年2月28日起在11家美国机构接受白细胞采集并计划接受标准治疗ide-cel的复发/难治性多发性骨髓瘤患者数据。
- 196例白细胞采集患者中,159例在数据截止时接受了ide-cel输注。
- 毒性按美国移植与细胞治疗学会指南分级,各机构按自身政策管理;疗效按国际骨髓瘤工作组反应标准评估。
主要发现
- 120例(75%)输注患者在白细胞采集时因合并症而不符合KarMMa临床试验入组条件。
- 任何级别和≥3级细胞因子释放综合征发生率分别为82%和3%,神经毒性发生率分别为18%和6%。
- 最佳总缓解率和≥完全缓解率分别为84%和42%。
- 中位随访6.1个月时,中位无进展生存期为8.5个月(95%CI,6.5至未达到),中位总生存期为12.5个月(95%CI,11.3至未达到)。
- 多变量分析显示,既往接受过BCMA靶向治疗、高危细胞遗传学、淋巴细胞清除时ECOG体能状态评分≥2以及较年轻年龄的患者无进展生存期更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates of 73% and 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel under the commercial Food and Drug Administration label. METHODS: Data were retrospectively collected from patients with RRMM who underwent leukapheresis as of February 28, 2022, at 11 US institutions with intent to receive SOC ide-cel. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines and managed according to each institution's policies. Responses were graded on the basis of the International Myeloma Working Group response criteria. RESULTS: One hundred fifty-nine of 196 leukapheresed patients received ide-cel by data cutoff. One hundred twenty (75%) infused patients would have been ineligible for participation in the KarMMa clinical trial because of comorbidities at the time of leukapheresis. Any grade and grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 82/3% and 18/6%, respectively. Best overall and ≥ complete response rates were 84% and 42%, respectively. At a median follow-up of 6.1 months from chimeric antigen receptor T infusion, the median progression-free survival was 8.5 months (95% CI, 6.5 to not reached) and the median overall survival was 12.5 months (95% CI, 11.3 to not reached). Patients with previous exposure to B-cell maturation antigen-targeted therapy, high-risk cytogenetics, Eastern Cooperative Oncology Group performance status ≥ 2 at lymphodepletion, and younger age had inferior progression-free survival on multivariable analysis. CONCLUSION: The safety and efficacy of ide-cel in patients with RRMM in the SOC setting were comparable with those in the phase II pivotal KarMMa trial despite most patients (75%) not meeting trial eligibility criteria.
引用
- Hansen DK, Sidana S, Peres LC, et al. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023. PMID: 36623248. doi:10.1200/JCO.22.01365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。